TY - JOUR
T1 - Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer
T2 - A Hoosier Oncology Group Protocol
AU - Blanke, C.
AU - Ansari, R.
AU - Mantravadi, R.
AU - Gonin, R.
AU - Tokars, R.
AU - Fisher, W.
AU - Pennington, K.
AU - O'Connor, T.
AU - Rynard, S.
AU - Miller, M.
AU - Einhorn, L.
PY - 1995/6
Y1 - 1995/6
N2 - Purpose: Here we report the results of a phase III study, to evaluate whether the addition of cisplatin to radiation therapy (XRT) would improve progression-free survival or overall survival for patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). Patients and Methods: Two hundred forty patients with biopsy-proven unresectable NSCLC without distant metastases or lower-stage medically inoperable patients were randomized to one of two treatment arms. Arm A consisted of thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy; and arm B consisted of identical XRT with the addition of cisplatin 70 mg/m2 every 3 weeks for three cycles beginning on the first day of irradiation. Results: Two hundred fifteen patients were eligible and assessable. The overall response rate was 50% on the combination arm versus 38% on the XRT- alone arm (P = .076). The median progression-free survival time was 23 versus 22 weeks, respectively (P = .0537). The median survival time was 43 weeks on the combination arm versus 46 weeks on the XRT arm (P(overall) = .3469). The 1-, 2-, and 5-year survival rates were 43%, 18%, and 5% on the combination arm versus 45% 13%, and 2% on the XRT arm, respectively. Conclusion: Cisplatin, administered every 3 weeks, does not significantly improve response rate, progression-free survival, or overall survival when added to thoracic XRT for locally advanced unresectable NSCLC.
AB - Purpose: Here we report the results of a phase III study, to evaluate whether the addition of cisplatin to radiation therapy (XRT) would improve progression-free survival or overall survival for patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). Patients and Methods: Two hundred forty patients with biopsy-proven unresectable NSCLC without distant metastases or lower-stage medically inoperable patients were randomized to one of two treatment arms. Arm A consisted of thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy; and arm B consisted of identical XRT with the addition of cisplatin 70 mg/m2 every 3 weeks for three cycles beginning on the first day of irradiation. Results: Two hundred fifteen patients were eligible and assessable. The overall response rate was 50% on the combination arm versus 38% on the XRT- alone arm (P = .076). The median progression-free survival time was 23 versus 22 weeks, respectively (P = .0537). The median survival time was 43 weeks on the combination arm versus 46 weeks on the XRT arm (P(overall) = .3469). The 1-, 2-, and 5-year survival rates were 43%, 18%, and 5% on the combination arm versus 45% 13%, and 2% on the XRT arm, respectively. Conclusion: Cisplatin, administered every 3 weeks, does not significantly improve response rate, progression-free survival, or overall survival when added to thoracic XRT for locally advanced unresectable NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=0029063353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029063353&partnerID=8YFLogxK
U2 - 10.1200/JCO.1995.13.6.1425
DO - 10.1200/JCO.1995.13.6.1425
M3 - Article
C2 - 7751888
AN - SCOPUS:0029063353
SN - 0732-183X
VL - 13
SP - 1425
EP - 1429
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -